JP7235316B2 - 新規ｔ細胞受容体およびそれを用いた免疫療法 - Google Patents

新規ｔ細胞受容体およびそれを用いた免疫療法 Download PDF

Info

Publication number
JP7235316B2
JP7235316B2 JP2019569676A JP2019569676A JP7235316B2 JP 7235316 B2 JP7235316 B2 JP 7235316B2 JP 2019569676 A JP2019569676 A JP 2019569676A JP 2019569676 A JP2019569676 A JP 2019569676A JP 7235316 B2 JP7235316 B2 JP 7235316B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019569676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529830A (ja
JP2020529830A5 (enExample
Inventor
ワグナー，クラウディア
アルテン，レオニー
ブンク，セバスティアン
マウラー，ドミニク
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Publication of JP2020529830A publication Critical patent/JP2020529830A/ja
Publication of JP2020529830A5 publication Critical patent/JP2020529830A5/ja
Application granted granted Critical
Publication of JP7235316B2 publication Critical patent/JP7235316B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019569676A 2017-06-30 2018-06-28 新規ｔ細胞受容体およびそれを用いた免疫療法 Active JP7235316B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762527844P 2017-06-30 2017-06-30
DE102017114737.3 2017-06-30
DE102017114737.3A DE102017114737A1 (de) 2017-06-30 2017-06-30 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US62/527,844 2017-06-30
PCT/EP2018/067380 WO2019002444A1 (en) 2017-06-30 2018-06-28 NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME

Publications (3)

Publication Number Publication Date
JP2020529830A JP2020529830A (ja) 2020-10-15
JP2020529830A5 JP2020529830A5 (enExample) 2021-08-12
JP7235316B2 true JP7235316B2 (ja) 2023-03-08

Family

ID=64662173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569676A Active JP7235316B2 (ja) 2017-06-30 2018-06-28 新規ｔ細胞受容体およびそれを用いた免疫療法

Country Status (22)

Country Link
US (5) US10590194B2 (enExample)
EP (1) EP3645573B1 (enExample)
JP (1) JP7235316B2 (enExample)
KR (1) KR20200023288A (enExample)
CN (1) CN110753705A (enExample)
AR (1) AR112604A1 (enExample)
AU (1) AU2018293322A1 (enExample)
BR (1) BR112019025323A2 (enExample)
CA (1) CA3067757A1 (enExample)
CL (1) CL2019003885A1 (enExample)
CO (1) CO2020000357A2 (enExample)
CR (1) CR20190594A (enExample)
DE (1) DE102017114737A1 (enExample)
IL (1) IL271751A (enExample)
MA (1) MA49503A (enExample)
MX (1) MX2019015742A (enExample)
MY (1) MY205262A (enExample)
PE (1) PE20200337A1 (enExample)
PH (1) PH12019502847A1 (enExample)
SG (1) SG11201911437VA (enExample)
TW (1) TWI727182B (enExample)
WO (1) WO2019002444A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术（广东）有限公司 一种识别ssx2的高亲和力t细胞受体
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
AU2024309123A1 (en) * 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014024914A1 (ja) 2012-08-08 2014-02-13 第一三共株式会社 ペプチド・ライブラリー及びその利用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2000006732A2 (en) * 1998-07-31 2000-02-10 Diagnostic Products Corporation Polynucleotide encoding an autoantigen associated with endometriosis
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
RU2739500C2 (ru) * 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях
EP3156067A1 (en) * 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
GB201520567D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014024914A1 (ja) 2012-08-08 2014-02-13 第一三共株式会社 ペプチド・ライブラリー及びその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Eur. J. Immunol.，1987年，vol. 17，p. 375-383

Also Published As

Publication number Publication date
US20200140540A1 (en) 2020-05-07
PH12019502847A1 (en) 2020-10-26
WO2019002444A9 (en) 2019-03-14
JP2020529830A (ja) 2020-10-15
CA3067757A1 (en) 2019-01-03
PE20200337A1 (es) 2020-02-14
EP3645573B1 (en) 2024-10-16
IL271751A (en) 2020-02-27
MX2019015742A (es) 2020-02-20
US11111294B2 (en) 2021-09-07
EP3645573A1 (en) 2020-05-06
CR20190594A (es) 2020-03-02
CL2019003885A1 (es) 2020-05-29
US20190002556A1 (en) 2019-01-03
WO2019002444A1 (en) 2019-01-03
US20190256590A1 (en) 2019-08-22
MY205262A (en) 2024-10-10
DE102017114737A1 (de) 2019-01-03
KR20200023288A (ko) 2020-03-04
TW201904989A (zh) 2019-02-01
US10590194B2 (en) 2020-03-17
US20210388079A1 (en) 2021-12-16
AR112604A1 (es) 2019-11-20
TWI727182B (zh) 2021-05-11
BR112019025323A2 (pt) 2020-06-23
MA49503A (fr) 2020-05-06
SG11201911437VA (en) 2020-01-30
US10723796B2 (en) 2020-07-28
CN110753705A (zh) 2020-02-04
US20250154246A1 (en) 2025-05-15
CO2020000357A2 (es) 2020-01-31
AU2018293322A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
JP7787119B2 (ja) Ｐｒａｍｅ陽性がんに対するｔ細胞受容体およびそれを用いた免疫療法
US20250154246A1 (en) Novel t cell receptors and immune therapy using the same
TWI735765B (zh) T細胞受體及其針對prame陽性癌症的免疫治療
TWI736719B (zh) 新型t 細胞受體及其免疫治療應用
JP2024153696A (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
AU2017373815B2 (en) Novel T cell receptors and immune therapy using the same
US20190359677A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230216

R150 Certificate of patent or registration of utility model

Ref document number: 7235316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD07 Notification of extinguishment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7427

Effective date: 20230901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230901